Status:

COMPLETED

Evaluation Of Linezolid Pk Profile In Burns Patients

Lead Sponsor:

Pfizer

Conditions:

Burns

Eligibility:

All Genders

18-60 years

Phase:

PHASE1

Brief Summary

Evaluation of linezolid pk profile in burns patients

Eligibility Criteria

Inclusion

  • Subject with a Body Mass Index (BMI) \< 30 kg/m\&#178;. For patient with major thermal injuries, the weight will be collected before the burn ;
  • Patients with major thermal injuries \>40% body area including 3rd degree burns with full thickness burns ;
  • Patients hospitalized for at least 10 days since their thermal injury occurred ;

Exclusion

  • Contra-indications to use linezolid as mentioned in the SmPC (Summarized Product Characteristics) : hypersensitivity to linezolid use or to any of its components, non-controlled hypertension, phaeochromocytoma, carcinoid syndrome, hyperthyroidism, bipolar disorders, schizoaffective disorders, acute confused state of mind, pregnancy, and breastfeeding ;
  • Drugs metabolised by monoamine oxydase (MAO) should be evaluated for potential drug-to-drug interaction;
  • Subject treated by: selective serotonin reuptake inhibitors (Prozac\&#174;, Effexor\&#174;, Ixel\&#174; \&#133;), tricyclic antidepressant (Anafranil\&#174;, Sinequan\&#174;, Surmontil\&#174;, Tofranil\&#174;), 5HT1 receptor agonists (triptan) direct or indirect sympathomimetic (including adrenergic bronchodilator, pseudoephedrine and phenylpropylamine), vasopressor (adrenaline and noradrenaline), dopaminergic drugs (dopamine, dobutamine), phenetidine or buspirone should be evaluated for potential drug-to-drug interaction;

Key Trial Info

Start Date :

May 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2007

Estimated Enrollment :

16 Patients enrolled

Trial Details

Trial ID

NCT00255996

Start Date

May 1 2006

End Date

January 1 2007

Last Update

July 14 2009

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Pfizer Investigational Site

Nantes, France, 44093

2

Pfizer Investigational Site

Paris, France, 75015

3

Pfizer Investigational Site

Paris, France, 75679